Introduction {#sec1}
============

The Human Proteome Project (HPP)^[@ref1]^ is an international project to characterize the human proteome through two programs: a chromosome-based strategy (C-HPP) designed in 2010^[@ref2],[@ref3]^ and the biology/disease-driven strategy (B/D-HPP).^[@ref4],[@ref5]^ Researchers from the chromosome-based strategy have used high throughput proteomics state-of-the-art technology, but major difficulties have arisen in the detection of a set of proteins, the so-called "missing proteins".^[@ref6]−[@ref8]^ These proteins lack experimental evidence obtained by mass spectrometry or antibody-based techniques, and their existence is based on bioinformatic predictions or transcriptomic analyses. In the C-HPP initiative, the reference database for the annotation of human proteins is neXtProt.^[@ref9]^ This database assigns experimental evidence to each human protein using a scale with five levels, from PE1 (experimental evidence at protein level) to PE5 (uncertain protein). The missing proteins are annotated as PE2 (experimental evidence at the transcript level), PE3 (protein inferred from homology), or PE4 (protein predicted). As a reference, the database version used in this study (release 01.09.2015) contained 20061 proteins, 16791 of them annotated as PE1 (83.70% of protein entries). The number of missing proteins was 2680, corresponding to 13.36% of the total entries in the database.

Several possibilities have been proposed to explain the difficulties in the detection of these proteins, including their low abundance, their tissue expression specificity, and their stimulation dependent or development associated expression. In fact, the different methodological approaches applied to characterize missing proteins have confirmed that the selection of the tissue or cell type is critical to the success of these experiments.^[@ref10]−[@ref13]^ One of the most widely used methods for the identification of the samples in which the probability of detection of missing proteins is higher takes into account the expression level of the corresponding transcripts. Therefore, the integration of genomics, transcriptomics, and proteomics is widely used among HPP groups in order to design the experiments needed to improve the annotation of the human proteome.^[@ref8]^ In particular, the Spanish Consortium of the HPP (spHPP), responsible for the study of chromosome 16, made a considerable effort to incorporate transcriptomic experiments as a tool for the analysis of the proteome. Public data sets from different resources such as the Gene Expression Omnibus (GEO) database^[@ref14]^ and the ENCODE project^[@ref15]^ were analyzed in depth to define the set of expressed genes in thousands of samples, including different biological sources (cell lines, normal tissues, and cancer samples) and technologies (microarrays and RNA-Seq).^[@ref16]^ In addition, a bayesian classifier was developed to score the probability of expression of the missing proteins in more than 3400 microarray experiments.^[@ref17]^ According to this study, testis, brain, and skeletal muscle were the best tissue candidates to detect the higher number of missing proteins using shotgun proteomics.

However, even when the analyzed sample is enriched in missing proteins, their identification is still challenging, especially when the bioinformatics methods and the statistical thresholds required impose stringent criteria to ensure the reliability of the observations resulting from the automatic MS data analysis and sequence assignments. Basically, the MS evidence for a protein is considered valid when the following conditions are fulfilled: 1% FDR at PSM, peptide and protein level, more than 1 peptide detected (9 or more amino acids in length) and at least two of which are not shared among the other proteins of the reference database (proteotypic peptides). The recent analysis of the human spermatozoa proteome^[@ref13]^ is a good example. In this study those proteins with only one peptide identification were filtered using the set of unique peptides of the missing proteins obtained from the *in silico* digestion of the neXtProt database. The remaining PSMs were manually evaluated by three independent experts, allowing the assignment of 94 new missing proteins. Finally, the expression of C2orf57 and TEX37 was validated by immunohistochemistry. This excellent result allowed us to reach two important conclusions: the high accuracy of the available methods to predict the sample of interest based on public transcriptomics and proteomics experiments and the need to develop new bioinformatic workflows and new methods of experimental validation able to circumvent the constraints inherent in the identification of the missing proteins.

In the field of proteomics, a huge amount of shotgun experiments are publicly available in different data repositories.^[@ref18]^ The most commonly used resources are the Global Proteome Machine Database (GPMDB, gpmdb.thegpm.org),^[@ref19]^ PeptideAtlas ([www.peptideatlas.org](www.peptideatlas.org)),^[@ref20]^ the ProteomeXchange consortium (<http://www.proteomexchange.org/>),^[@ref21]^ and the PRIDE database.^[@ref22]^ More specifically, the members of the ProteomeXchange Consortium are working to standardize data submission and dissemination practises in the field. All proteomic experimental data sets in the HPP must be submitted to any of the ProteomeXchange resources. The stored data types include raw mass spectra data, peak lists, sample metadata, and the results of the original analyses (identification and quantification of peptides and proteins). Only the PRIDE Archive database contains at present more than 5000 data sets, including more than 60000 assays.

In this manuscript, we used public MS experiments to obtain guidance in the search for missing proteins. Initially, we assessed the possibility of obtaining information about the samples in which the number of missing proteins is enriched using the PRIDE database. This approach confirmed the results obtained using transcriptome profiles and provided new biological sources to be explored. The experiments selected were downloaded from the database and studied using two data analysis workflows. The number of missing proteins identified by our bioinformatics workflow, based on the analysis of the intersection of the PSM FDR filtering of the experimental results with the proteotypic peptides obtained from the *in silico* analysis of the reference database (without FDR filtering at protein level), was higher than the number of missing proteins detected applying the HPP guidelines. Upon manual inspection and curation, the best spectral assignments corresponding to chromosome 16 or detected in the HEK293 cell line were validated using SRM. Data are provided supporting the detection of DNAH3 in the spermatozoa sample. Moreover, ATAD3C and UNCX proteins, previously related to embryonic development, were also detected in the shotgun experiments, and more interestingly, ATAD3C was confirmed by the LC-SRM experiments.

Materials and Methods {#sec2}
=====================

Analysis Workflow {#sec2.1}
-----------------

We applied an analysis approach based on the detection of proteotypic peptides in shotgun experiments using FDR filtering at the PSM level^[@ref13]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), and the results obtained in terms of the number of missing proteins were compared with those resulting from the analysis recommended in the HPP Data Interpretation Guidelines version 2.0.1 (approved 2015-12-01). However, a major issue to be previously addressed was the selection of the samples to be analyzed in order to increase the chance of successful missing protein identifications. Different approaches had been previously described to select the biological source in which this probability is higher based on gene transcription profiles.^[@ref8],[@ref17]^ We propose a new prediction which is based on publicly available MS/MS experiments. The PRIDE database was examined^[@ref22]^ to obtain the set of experiments in which the number of peptide candidates from the missing proteins is higher ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![(A) Overall scheme of the analysis pipeline developed to identify missing proteins using the PRIDE database. (B) Summary of the numbers of proteins and peptides in each step of the analysis pipeline developed.](pr-2016-00437s_0001){#fig1}

Data Processing of PRIDE and neXtProt Databases {#sec2.2}
-----------------------------------------------

This study was based on the data mining of public human data sets in the PRIDE Archive database (April 2015), which contained at the time 47409216 PSMs, distributed in 242 projects and 7295 assays. The database included 6001962 unique human peptides and 559405 different protein accession codes obtained using several search engines, including Mascot, Sequest, X!Tandem, OMSSA, and Phenyx. Although we performed a complete proteome analysis of the samples selected for the study of the missing proteins, the selection of the proper experiments was carried out using only the human PSMs from the missing proteins of chromosome 16. We expected there to be a certain proportionality between the number of peptides from the missing proteins detected in a shotgun experiment and the number of missing proteins present in the sample, although the information about the search engine and the statistical reliability of the identifications was not considered.

Proteogest software^[@ref23]^ was used to perform the *in silico* digestion of all the proteins contained in the reference database (neXtProt release 20150901). We applied the standard rules of trypsin digestion and allowed oxidation of methionine and two missed cleavages. The processing of the set of tryptic peptides obtained allowed us to find all the proteotypic peptides. In this manuscript, we use the theoretical definition of proteotypic peptide: a peptide generated after the digestion of a protein using a certain enzyme (commonly trypsin) that can only be detected in one protein, without taking into account experimental data or a bioinformatics prediction of MS detectability of the peptide.

Shotgun Data Analysis Using HPP Guidelines {#sec2.3}
------------------------------------------

The selected data sets were analyzed for protein identification following the HPP guidelines. We searched all the mgf files downloaded from PRIDE against the neXtProt database (release 20150901) using the target-decoy strategy with an in-house Mascot Server v. 2.3 (Matrix Science, London, U.K.) search engine. A decoy database was created using the peptide pseudoreversed method, and separate searches were performed for target and decoy databases.

For each sample, searching parameters were fixed on the basis of the information provided in the metadata associated with the project in PRIDE or by the methods described in the referenced article. False Discovery Rates at the PSM level and protein level using Mayu^[@ref24]^ were calculated, and protein identifications were obtained applying the criteria of PSM FDR \< 1% and protein FDR \< 1%. Protein inference was performed using the PAnalyzer algorithm.^[@ref25]^ Only those missing proteins labeled as conclusive by this algorithm and with at least 2 proteotypic peptides were considered as observed missing proteins in the sample.

Detection of Proteotypic Peptides in Shotgun Experiments {#sec2.4}
--------------------------------------------------------

We propose an alternative analysis of the proteomics experiments to increase the number of missing proteins detected without a significant loss of the quality of the results ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). This pipeline used the PSMs with PSM FDR \< 1%, and the peptides identified using this criteria were intersected with the set of proteotypic peptides obtained after the *in silico* digestion of all the amino acid sequences of the neXtProt database. This approach ensured that the proteins obtained had at least one peptide capable of discriminating them from the rest of the proteins in the reference database. Finally, the spectra assignments of the peptides potentially corresponding to missing proteins were manually curated to select the best candidates. Further verification by SRM was conducted in the indicated matrices. Nevertheless, an estimation of the protein FDR value was obtained by processing the results against the decoy database in a similar way. We performed the *in silico* digestion of the decoy database and extracted the proteotypic peptides. We used the minimum Mascot ion score of the target proteotypic peptides with PSM FDR \< 1% to estimate the number of false protein identifications using the decoy proteotypic peptides with a higher score. The FDR at the protein level was calculated as the ratio between the number of decoy proteins and the number of target proteins detected.

Sample Collection and Preparation {#sec2.5}
---------------------------------

Sperm samples (more than 30 million cells) and HEK293 cells were centrifuged at 800*g* for 10 min. The supernatant of sperm samples (seminal plasma) was removed and saved in a cryotube. The cellular pellet was washed twice with 1.5 mL of PBS, frozen in liquid nitrogen, and stored at −20 °C until use. The pelleted cells were thawed and disrupted by addition of lysis buffer (8 M urea, 2 M thiourea, and 4% CHAPS) and vigorous agitation in a vortex for 30 min at room temperature. Cell debris was removed by centrifugation at 24100*g* for 10 min. The supernatants were stored at −20 °C until use. The protein concentration of the supernatant was determined using the Bio-Rad RC DC Protein Assay Kit (\#500-0122).

Targeted Proteomic Analyses (SRM/MRM) {#sec2.6}
-------------------------------------

Total cell extracts were loaded into 1D SDS-PAGE gel and run until the sample just entered the resolving gel. Gels were fixed (50% methanol/10% acetic acid), stained with Coomassie (Simply Blue Safe Stain, Invitrogen), washed to reveal the unique band containing the whole proteome, and subjected to in gel trypsin digestion. Briefly, the gel section was destained twice with AcN for 5 min at 40 °C, removing the liquid to complete dryness of the gel. Proteins were reduced and alkylated with 10 mM DTT/100 mM ammonium bicarbonate and 28 mM iodoacetamide/100 mM ammonium bicarbonate, respectively, for 10 min at 40 °C. Subsequently, gel pieces were dried with AcN for 5 min at 40 °C, removing the supernatant to complete dryness. Proteins were digested with trypsin (Promega) using a 1:20 trypsin/protein ratio overnight at 37 °C. Peptide extraction was performed with consecutive incubations (30 min, room temperature) with 1% formic acid/2% AcN; 05% formic acid/50% AcN; 100% AcN. All supernatants were combined and evaporated to dryness in a speed-vac. Peptides were solubilized in 1% trifluoroacetic acid and further extracted using a C18 reverse phase sorvent (Pierce C18 Spint Tips) following the manufacturer's protocol. Extracted peptides were dried in a speed-vac before nLC ESI-MS/MS analysis.

A total of 17 proteotypic peptides were selected, and isotopically labeled standards were synthesized. Peptide standards were prepared at 500, 125, 25, and 5 fmol/μL in 2% acetonitrile, 0.1% FA. Two microliters of the solutions were analyzed in a Qtrap5500 (ABSciex) coupled to a nanoflow high performance HPLC (Eksigent) equipped with a nanoelectrospray ion source. Mobile phases were A (100% H~2~O and 0.1% formic acid) and B (100% AcN and 0.1% formic acid). Peptides were separated by C18 reverse phase chromatography at a flow rate of 0.3 μL/min in an Acclaim Peptide Map RSLC 75 μm (column ID) × 150 mm (column length) × 2 μm (particle size) analytical column, using the gradient: 0 min, 3%B; 3 min, 3%B; 90 min, 40%B; 100 min, 50%B; 102 min, 90%B; 108 min, 90%B; 110 min, 3%B; 125 min, 3%B. Electrospray parameters used were: CUR = 20; CAD = high; IS = 2800; GS1 = 20; GS2 = 0; and IHT = 150. The collision energy and declustering potential applied to each peptide was calculated with the skyline software. The dwell time for each transition was 20 ms for the synthetic heavy peptides and 100 ms for the endogenous peptides.

The raw MS proteomics data have been deposited in PeptideAtlas^[@ref20]^ PASSEL with accession code PASS00925.

Results and Discussion {#sec3}
======================

Sample Selection Based on the PRIDE Database Content {#sec3.1}
----------------------------------------------------

We found 601 proteotypic peptide candidates in the neXtProt (release 20150101) in 65 PRIDE projects, which suggests the presence of 102 missing proteins of chromosome 16 with 2630 PSMs. The number of detected peptides in each project is shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. This bar plot was used to select the project accession codes in which the expected number of missing proteins of chromosome 16 was higher (at least 50 peptides associated with missing proteins).

![Number of proteotypic peptides of chromosome 16 missing proteins in the neXtProt database that were detected in the shotgun MS/MS experiments stored in the PRIDE database. The experiments selected for further analyses are highlighted in red.](pr-2016-00437s_0002){#fig2}

However, the PRIDE database is constantly changing, incorporating experiments as new proteomic data sets are submitted. We tried to consider this dynamic behavior as far as possible and included new samples in the study during the development of the project. Consequently, we included 4 samples from rare biological sources, since it had been proved that these samples can be used to detect missing proteins:^[@ref13]^ spermatozoid,^[@ref13]^ seminal plasma,^[@ref26]^ retina,^[@ref27]^ and placenta.^[@ref28]^ In addition to that, we included a most recent proteome characterization of the HEK293 cell line^[@ref29]^ in replacement of the experiment with PRIDE accession number PXD001383. The list of projects selected from the PRIDE database for analysis is shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

###### Project Accessions of the PRIDE Database Selected for the Identification of Missing Proteins[a](#tbl1-fn1){ref-type="table-fn"}

  Project Accession   Tissue            Instrument           ⧧ samples   ⧧ fractions
  ------------------- ----------------- -------------------- ----------- -------------
  PXD001468           HEK293            Q Exactive           1           24
  PXD002367           Spermatozoid      LTQ Orbitrap         1           21
  PXD001242           Retina            LTQ Orbitrap Elite   5           60
  PXD000754           Placenta          LTQ Orbitrap         2           47
  PXD000605           Blood plasma      LTQ Orbitrap         3           146
  PXD000004           Frontal cortex    Q Exactive           5           14
  PRD000269           Aorta thoracica   LTQ Orbitrap         1           108
  PXD002145           Seminal plasma    LTQ Orbitrap Elite   2           96

The number of samples and fractions analyzed in this study are shown.

*In Silico* Analysis of the neXtProt Database {#sec3.2}
---------------------------------------------

The total number of peptides obtained was 7031853 (2958508 unique peptides), and 8.81% of the unique peptides corresponded to missing proteins. The mean number of peptides per protein for the missing proteins was 116, whereas the mean number of peptides for the nonmissing proteins was 180. This was in accordance with a previous analysis of the features of the missing proteins,^[@ref17]^ in which it is shown that these proteins are shorter. The set of proteotypic peptides (tryptic peptides not shared among proteins of the neXtProt database) was generated using in-house scripts. The number of proteotypic peptides ranging from 9 to 30 amino acids in length was 826137, 10.59% of which were assigned to missing proteins (87545 peptides).

The number of tryptic and proteotypic peptides discovered using the amino acid sequences of the neXtProt database for each chromosome is shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B, respectively. The mean number of proteotypic peptides per chromosome was 3498 for the missing proteins and 29552 for the nonmissing proteins. The number of proteins that contained at least one tryptic peptide with a length between 9 and 30 amino acids was 20028. Interestingly, 19410 proteins, almost all of the proteins detectable with tryptic peptides, had also at least one proteotypic peptide. The number of missing proteins that could be detected by at least one proteotypic peptide was 2533, 94.94% of the missing proteins in the neXtProt database. There were 2496 with two or more proteotypic peptides, 37 with only one and 135 without any predictable tryptic and proteotipic peptide, which will not be detectable according to the HPP guidelines using trypsin ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_001.xlsx) Table 1). For these 95 proteins, other experimental approaches must be developed, for example the use of other enzymes for protein digestion.

![(A) Distribution of tryptic peptides deduced from *in silico* digestion of the neXtProt database (release 20150901) along chromosomes. (B) Distribution of proteotypic peptides deduced from the *in silico* digestion of the neXtProt database (release 20150901) along chromosomes. (C) Distribution of proteins with at least one tryptic peptide after the *in silico* digestion of the neXtProt database (release 20150901) along chromosomes. (D) Distribution of proteins with at least one proteotypic peptide after the *in silico* digestion of the neXtProt database (release 20150901) along chromosomes.](pr-2016-00437s_0003){#fig3}

In [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D we represent the distribution of these proteins across chromosomes. The mean number of proteins with at least one tryptic peptide per chromosome was 801, and that with at least one proteotypic peptide was 777. In the case of the missing proteins, the average number of proteins per chromosome with at least one proteotypic peptide was reduced to 101 proteins.

With regard to chromosome 16, there are 836 proteins with at least one tryptic peptide and 813 with at least one proteotypic peptide with a length between 9 and 30 amino acids. 11.12% of tryptic proteins and 11.19% of proteotypic proteins are still considered missing proteins (93 tryptic and 91 proteotypic proteins).

Identification of Conclusive Missing Proteins {#sec3.3}
---------------------------------------------

In order to perform the analysis of the missing proteins for all the chromosomes, we used more than 5 million spectra that were available in the selected projects from the PRIDE database. After the independent analysis of each of the experiments downloaded from the PRIDE database following the HPP guidelines, we assigned 503054 of these spectra (9.77%) and we identified 5284 proteins with 1 or more proteotypic peptides and 3950 proteins with 2 or more proteotypic peptides. We detected 58 missing proteins with 1 or more proteotypic peptides and 32 proteins with 2 or more proteotypic peptides ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_003.xlsx) Table 3).

The results from each sample analysis are summarized in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. Spermatozoid (PXD002367) and the HEK293 cell line (PXD001468) were the samples with the higher number of missing proteins detected. This result was consistent with previous analyses of the spermatozoid proteome,^[@ref13]^ and it revealed the HEK293 cell line as a new biological source of missing proteins. However, we did not find any evidence of the presence of missing proteins in placenta (PXD000754), blood plasma (PXD000605), frontal cortex (PXD000004), aorta thoracica (PRD000269), and seminal plasma (PXD002145) samples.

Detection of Missing Proteins Using Proteotypic Peptides {#sec3.4}
--------------------------------------------------------

Our objective is to increase the number of missing protein detections in the human proteome using the selected PRIDE data sets with an alternative bioinformatics pipeline based on the identification of proteotypic peptides deduced from the proteins of interest. In this strategy, we retained the protein identifications that failed to pass the FDR criteria at a protein level of 1%. The PSMs obtained with the Mascot search engine (search parameters were previously shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) with PSM FDR \< 1% were used to identify all potential tryptic peptides from the proteins present in the samples ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_002.xlsx) Table 2). Finally, this set of peptides were intersected with the proteotypic peptides found after the *in silico* digestion of the neXtProt database.

###### Parameters Used in the Mascot Search Engine for the Analysis of Each Downloaded Project from the PRIDE Database

  Project Accession         Precursor mass tolerance (ppm)   Fragment mass tolerance (Da)   Missed cleavages   Fixed modifications   Variable modifications
  ------------------------- -------------------------------- ------------------------------ ------------------ --------------------- ------------------------
  PXD001468                 20                               0.05                           2                  Carbamidomethyl (C)   Oxidation (M)
  PXD002367                 10                               0.5                            2                  Carbamidomethyl (C)   Oxidation (M)
  Acetyl (Protein N-term)                                                                                                            
  PXD001242                 20                               0.05                           2                  Carbamidomethyl (C)   Oxidation (M)
  PXD000754                 20                               1                              2                  Carbamidomethyl (C)   Oxidation (M)
  PXD000605                 20                               0.05                           2                  iTRAQ4plex114 (K)     iTRAQ4plex114 (Y)
  Methylthio (C)            Oxidation (M)                                                                                            
  PXD000004                 20                               0.05                           2                  Carbamidomethyl (C)   Oxidation (M)
  Label: 13C(6) (K)                                                                                                                  
  PRD000269                 20                               0.05                           2                  Carbamidomethyl (C)   Oxidation (M)
  PXD002145                 10                               0.5                            2                  Carbamidomethyl (C)   Oxidation (M)
  Acetyl (Protein N-term)                                                                                                            

###### Number of PSMs, Peptides, and Proteins Identified Using the HPP Guidelines (PSM FDR \< 1%, protein FDR \< 1%) in the Samples Selected from PRIDE for the Analysis of the Missing Proteins[a](#tbl3-fn1){ref-type="table-fn"}

                                       PXD001468   PXD002367   PXD001242   PXD000754   PXD000605   PXD000004   PRD000269   PXD002145   Total
  ------------------------------------ ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ---------
  Spectra                              836145      114970      452880      519326      1299378     357899      370218      1198042     5148858
  Total PSMs                           328554      48609       110624      80213       19086       136506      21969       6676        752237
  FP PSMs                              161         34          136         201         5           154         11          116         818
  Total Peptides                       68377       9848        14413       10122       1228        16679       2001        199         93012
  Total Peptides (proteotypic)         24510       3990        5393        4226        788         5737        746         56          33756
  Total Peptides (nonproteotypic)      43867       5858        9020        5896        440         10942       1255        143         59256
  FP Peptides                          70          12          20          46          2           41          3           8           202
  Total Proteins                       7206        1437        2681        2127        363         2340        351         54          8712
  Total Conclusive Prot                4539        909         1501        1140        146         1069        193         29          5626
  FP Proteins                          33          8           15          11          2           33          1           8           111
  Total Assigned Spectra               191095      24736       66707       51392       18091       133602      14936       2495        503054
  Missing PSMs                         798         473         117         0           0           0           0           0           1388
  Missing Peptides                     83          258         25          0           0           0           0           0           357
  Missing Proteins                     10          47          5           0           0           0           0           0           60
  Missing Assigned Spectra             479         367         68          0           0           0           0           0           914
  Total Proteins HPP (≥1 peptide)      4276        888         1450        1115        146         1053        188         28          5284
  Total Proteins HPP (≥2 peptides)     3326        750         1260        1000        120         924         169         22          3950
  Missing Proteins HPP (≥1 peptide)    10          45          5           0           0           0           0           0           58
  Missing Proteins HPP (≥2 peptides)   5           27          1           0           0           0           0           0           32

FP = false positives.

This approach allowed us to detect a total of 6333 proteins, 1049 more than the proteins identified with the HPP guideline analysis. With regard to the number of peptides identified, we obtained 35922 proteotypic peptides with PSM FDR \< 1%, representing an increase of 6.42% over the peptides detected with the previous method. In order to achieve these results, 515506 spectra were assigned, a slight increase (0.24%) in the percentage of spectra used from the total number of spectra available in the data sets. This led to the inclusion of 12452 new spectra in the analysis ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}).

###### Number of PSMs, Peptides, and Proteins Observed Using the Identifications of Proteotypic Peptides from the neXtProt Database (PSM FDR \< 1%) in the Samples Selected from PRIDE for the Analysis of the Missing Proteins

                                    PXD001468   PXD002367   PXD001242   PXD000754   PXD000605   PXD000004   PRD000269   PXD002145   Total
  --------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ---------
  Spectra                           836145      114970      452880      519326      1299378     357899      370218      1198042     5148858
  Total PSMs                        332417      49100       115861      82856       19182       138704      23199       6676        767995
  Total Peptides                    71277       10311       16329       11739       1271        17570       2521        199         98319
  Total Peptides (proteotypic)      25734       4187        6259        4848        804         6092        988         56          35922
  Total Peptides (nonproteotypic)   45543       6124        10070       6891        467         11478       1533        143         62397
  Total Proteins (≥1 peptide)       5341        1293        2420        2208        245         1929        569         41          6333
  Total Proteins (≥2 peptides)      3326        750         1260        1000        120         924         169         22          3950
  Total Assigned Spectra            193971      25083       71118       53398       18187       135285      15969       2495        515506
  Missing PSMs                      96          246         33          22          0           14          4           0           415
  Missing Peptides                  48          163         14          10          0           8           4           0           242
  Missing Proteins (≥1 peptide)     30          67          14          10          0           8           4           0           122
  Missing Proteins (≥2 peptides)    8           30          3           2           0           2           2           0           39
  Missing Assigned Spectra          62          195         29          16          0           14          4           0           320

The mean value of the FDR estimation at protein level was 8%. This value is higher than the threshold recommended by the HPP guidelines, but it provided high quality results after a manual curation of the assigned spectra.

Focusing on missing proteins, 122 were potentially identified ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_004.xlsx) Table 4), 62 proteins more than those detected as conclusive proteins by PAnalyzer, and only 242 peptides were needed compared with the 357 peptides obtained after the protein inference process. Seminal plasma (PXD002145) and blood plasma (PXD000605) were the only samples where we did not find any evidence of the presence of missing proteins. We also observed differences in the number of spectra assigned, 320 in this analysis and 914 in the previously described. This result is consistent with the basis of our method, since it only allows for proteotypic peptide detection.

Peptide distribution along chromosomes showed that the number of proteotypic peptides was a small fraction of the total number of peptides observed ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Moreover, we obtained a statistically significant lower Mascot ion score for the peptides from the missing proteins compared with the ion score of the peptides from the nonmissing proteins (*t* test statistic with a *p*-value \<1 × 10^--16^, see [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Unsurprisingly, the proportion of missing proteins detected per chromosome was very small, although assignments were made in all chromosomes, with the only exception that of mitochondria ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). As might be expected, the comparison of the missing proteins detected by the two bioinformatic pipelines ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}D) showed that the majority of proteins detected using HPP guidelines were included in the set of missing proteins with proteotypic peptides.

![(A) Distribution of tryptic and proteotypic peptide candidates detected in the analyzed samples along the different chromosomes. (B) Boxplot with the distribution of Mascot ion scores obtained for the PSMs assigned to missing and nonmissing proteins. The difference between these distributions is statistically significant with a *p*-value \< 1 × 10^--12^. (C) Distribution of missing and nonmissing proteins potentially detected in the analyzed samples using the identification of proteotypic peptides along chromosomes. (D) Venn diagram with the missing proteins observed using the HPP guidelines and the workflow proposed here and with the missing proteins in neXtProt database release 20150901.](pr-2016-00437s_0006){#fig4}

In spite of the tissue specificity of the missing proteins, we found a few examples of shared proteins between samples ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). The diagonal of the heat map represents the number of missing proteins identified in each sample, and the rest of the matrix is filled with the number of missing proteins common to each pair of samples. It is easy to verify that the majority of the protein identifications were sample specific. The visualization of the results was improved using a network to represent in an effective way the relations between the samples studied, the missing proteins observed, and the peptides detected ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). This graph could be completed including the results of the analysis of more proteomic data sets in order to generate the network of the missing proteins of the human proteome.

![(A) Heat map with the missing proteins potentially detected in each sample and the missing proteins shared between each pair of samples analyzed. (B) Network representation of the results obtained for the study of the missing proteins using the PRIDE database. Nodes represent the database of experiments used (green), the tissue (orange), the proteins observed (red), and the identified peptides (blue). (C) Network for the missing proteins potentially observed in the HEK293 sample. Nodes represent the sample selected (green), the chromosome (blue), and the identified protein (red). (D) Network for the missing proteins potentially detected in chromosome 16. Nodes represent the sample (orange), the proteins observed (red), and the identified peptides (blue).](pr-2016-00437s_0007){#fig5}

Missing Proteins Identified in the HEK293 Cell Line or from Chromosome 16 {#sec3.5}
-------------------------------------------------------------------------

The network of the missing proteins was used to extract information about the proteins observed to perform functional analysis of protein sets and to select peptides for validation. In our case, we decided to continue the analysis of the missing proteins detected in the HEK293 cell line (PXD001468, shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C), as it is different from previous studies focused on testis and sperm or encoded by chromosome 16, genes as this is the chromosome adopted by the Spanish team in chromosome 16 ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D). In [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"} the 34 proteins corresponding to 33 known genes found in the HEK293 cell line or chromosome 16 are shown. These proteins are a subset of the total of the proteins obtained using the detection of proteotypic peptides ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_004.xlsx) Table 4).

###### Missing Proteins Potentially Identified Using Proteotypic Peptide Candidates in the HEK293 Cell Line or in Chromosome 16

  Protein     Name       Chr   no. PSMs   no. Peptides   Ion score   HPP guidelines (2 proteotypic peptides)   Sample
  ----------- ---------- ----- ---------- -------------- ----------- ----------------------------------------- --------------------------
  NX_A6NJT0   UNCX       7     8          4              113.22                                                HEK
  NX_B2RXH8   HNRNPCL2   1     276        15             102.61                                                HEK,Retina
  NX_Q9BQ87   TBL1Y      Y     76         10             100.66                                                HEK
  NX_Q2VIQ3   KIF4B      5     46         19             99.77       √                                         HEK
  NX_Q6IS14   EIF5AL1    10    298        17             95.03       √                                         HEK
  NX_Q5T2N8   ATAD3C     1     56         8              85.06       √                                         HEK,Retina
  NX_Q56UQ5   \-         X     55         4              81.79       √                                         HEK
  NX_Q8TD57   DNAH3      16    27         25             80.77       √                                         Spermatozoa,Retina
  NX_Q6URK8   TEPP       16    17         10             79.62                                                 Spermatozoa
  NX_Q9NRJ5   PAPOLB     7     10         3              77.63       √                                         HEK
  NX_Q6ZR08   DNAH12     3     34         23             75.04       √                                         Placenta,HEK,Spermatozoa
  NX_A8K0S8   MEIS3P2    17    6          1              58.75       √                                         HEK
  NX_Q6ZMV8   ZNF730     19    3          3              58.21       √                                         HEK
  NX_Q14585   ZNF345     19    1          1              57.3        √                                         HEK
  NX_Q52M93   ZNF585B    19    1          1              54.08       √                                         HEK
  NX_Q9UJN7   ZNF391     6     4          3              53.79       √                                         HEK
  NX_P58180   OR4D2      17    3          1              52.28       √                                         HEK,Spermatozoa
  NX_Q8NGL6   OR4A15     11    3          1              52.28                                                 Spermatozoa,HEK
  NX_P59817   ZNF280A    22    1          1              48.17                                                 HEK
  NX_A6NHN6   NPIPB15    16    7          5              47.7        √                                         Spermatozoa
  NX_Q9Y2H8   ZNF510     9     1          1              45.02                                                 HEK
  NX_Q96KX1   C4orf36    4     1          1              44.7        √                                         HEK
  NX_Q96M86   DNHD1      11    1          1              44.16                                                 HEK
  NX_Q5VTU8   ATP5EP2    13    1          1              43.65       √                                         HEK
  NX_Q8N0W5   IQCK       16    1          1              43.57       √                                         Spermatozoa
  NX_Q4AC99   ACCSL      11    1          1              43.57       √                                         HEK
  NX_A6NNF4   ZNF726     19    2          1              43.39       √                                         HEK
  NX_P0CW27   CCDC166    8     1          1              40.88       √                                         HEK
  NX_A6NCM1   IQCA1L     7     1          1              40.63       √                                         HEK
  NX_Q8NDH2   CCDC168    13    1          1              40.58       √                                         HEK
  NX_Q6R2W3   ZBED9      6     1          1              40.51       √                                         HEK
  NX_A6NN73   GOLGA8CP   15    1          1              40.35       √                                         HEK
  NX_Q9H2H0   CXXC4      4     1          1              39.19       √                                         HEK
  NX_Q9BXX2   ANKRD30B   18    3          2              39.01       √                                         Aorta,HEK

Functional Analysis of the Missing Proteins {#sec3.6}
-------------------------------------------

The functional analysis of the list of the 182 missing proteins detected was performed, and a good correlation between the results obtained and the sample types analyzed was found. We used DAVID v6.7 software^[@ref30]^ for the analysis of GO terms, INTERPRO domains, KEGG pathways, PANTHER pathways, and UNIGENE quantile expression level gene sets using the whole human proteome as the background list of proteins. The statistical analysis was performed using default parameters, and although the *p*-value was corrected using the multiple hypothesis methods (including FDR), the selection of enriched categories was based on a criterion of EASE Score \< 0.1, as suggested by the bioinformatics tool. Using these recommended settings, we found a list of enriched categories related with specific functions carried out by these proteins in the samples analyzed ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_005.xlsx) Table 5). First, the tissue specific expression gene ontology analysis for these genes using the "UNIGENE EST QUARTILE" expression profile database showed statistical enrichment in "brain normal" with 44 genes and a *p*-value = 0.003, "embryo development" with 51 genes and a *p*-value = 0.01, and "testis normal" with 67 genes and a *p*-value = 2.73 × 10^--14^, confirming the sample specificity of the missing proteins detected. The results of the enrichment analysis of GO terms showed categories previously related to spermatozoa function,^[@ref13]^ such as "microtubule-based movement", "sexual reproduction", "integral to membrane", or "motor activity". Other enriched categories were related to brain tissues or neurological processes, such as "sensory perception", "neurological system process", "cognition", or "postsynaptic membrane". Finally, others were involved in cell differentiation ("transcription" or "DNA binding"). We also compared the categories obtained with those previously defined with a similar functional analysis of all the missing proteins,^[@ref17]^ and many overlaps were found: "G-protein coupled receptor protein signaling pathway", "integral to membrane", "olfactory receptor activity", or some Interpro domains ("zinc finger, C2H2-type", "GPCR, rhodopsin-like superfamily").

A complementary functional and pathway analysis of this protein set was carried out using QIAGEN Ingenuity Pathway Analysis ([www.ingenuity.com](www.ingenuity.com)). As expected, we found a lack of enrichments or networks of interest due to the curated database on which this software is based. The missing proteins are proteins without experimental evidence, and in most of the cases, this is linked to scarce bibliographic information about them or their coding genes. However, interesting relationships were found between the protein WBP2NK (a sperm-specific WW domain-binding protein that promotes meiotic resumption and pronuclear development during oocyte fertilization) and "reproductive system development and function"; proteins CNGA2 (Cyclic Nucleotide Gated Channel Alpha 2) and PLCZ1 (Phospholipase C, Zeta 1, a protein that localizes to the acrosome in spermatozoa and elicits Ca(2+) oscillations and egg activation during fertilization) and "sperm mobility"; and UNXC (UNC Homeobox, a transcription factor involved in somitogenesis and neurogenesis and required for the maintenance and differentiation of particular elements of the axial skeleton) and "embryonic development".

Manual Evaluation of PSMs and Selection of Peptides {#sec3.7}
---------------------------------------------------

As we have previously mentioned, the estimated protein FDR for the proteins selected was 8%. In order to minimize the influence of this value on the quality of the results, we performed additional filtering steps to select the peptides for experimental validation. First, we selected the peptides with less than 20 amino acids in length, due to the limitation in the synthesis of heavy peptides for SRM/MRM experiments. For each remaining peptide of chromosome 16 or the HEK293 cell line, we chose its best PSM using the maximum Mascot ion score. This resulted in a total of 59 peptides, 43 of which were observed in the HEK293 cell line and 16 of which were observed chromosome 16.

The last stage consisted of a manual curation of the assigned spectra by three mass spectrometry experts. The 59 spectra were visualized and evaluated using the software SeeMS 3.0.7106.0 from ProteoWizard platform for proteomics data analysis,^[@ref31]^ according to the following features:^[@ref32]^ (a) the quality of the y-ion and b-ion series assignments; (b) the peak intensities and observed signal-to-noise ratio; (c) the number of nonassigned peaks. Only the PSMs considered as "high quality" by the three experts were considered for further analysis. For illustrative purposes, we show in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} four PSMs corresponding to two peptides selected from chromosome 16 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A and [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B) and one peptide from the HEK293 cell line ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}C and [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}D). The complete list of the 17 peptides selected for validation by SRM/MRM can be found in [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"}.

![(A) Spectra assignment of peptide LYSSLLDEIR from protein NX_Q8TD57 (DNAH3, chromosome 16) detected with Mascot ion score 75.99 in spermatozoa. (B) Spectra assignment of peptide TQTISLGQGQGPIAAK from protein NX_Q8TD57 (DNAH3, chromosome 16) detected with Mascot ion score 80.77 in spermatozoa. (C) Spectrum assignment of peptide DAASCGPGAAVAAVER from protein NX_A6NJT0 (UNCX, chromosome 7) detected with Mascot ion score 113.22 in HEK293 cell line.](pr-2016-00437s_0008){#fig6}

###### Peptides Selected for Validation Using Targeted Proteomics (SRM/MRM)

  Protein     Name       Peptide             Chr   Sample        Ion score   Missing in neXtProt20160111   HPP guidelines (2 proteotypic peptides)
  ----------- ---------- ------------------- ----- ------------- ----------- ----------------------------- -----------------------------------------
  NC_A6NJT0   UNCX       DAASCGPGAAVAAVER    7     HEK           113.22      √                             √
  NC_Q9BQ87   TBL1Y      IWTENGNLASTLGQHK    Y     HEK           93.62       √                             √
  NC_Q8TD57   DNAH3      TQTISLGQGQGPIAAK    16    Spermatozoa   80.77                                     √
  NC_Q8TD57   DNAH3      LYSSLLDEIR          16    Spermatozoa   75.99                                     √
  NC_Q2VIQ3   KIF4B      EMCDMEQVLSK         5     HEK           67.29       √                             √
  NC_Q5T2N8   ATAD3C     AAGTLFGEGFR         1     HEK           66.45       √                              
  NC_Q2VIQ3   KIF4B      NLELEVINLQK         5     HEK           64.73       √                             √
  NC_A8K0S8   MEIS3P2    MVQPMIDQSNR         17    HEK           58.75       √                              
  NC_Q8TD57   DNAH3      EANVAAAIAQGIK       16    Spermatozoa   49.37                                     √
  NC_A6NHN6   NPIPB15    ADEVEQSPKPK         16    Spermatozoa   47.7        √                              
  NC_Q8N0W5   IQCK       AGEPFTEFFSIPFVEER   16    Spermatozoa   43.57       √                              
  NC_B2RXH8   HNRNPCL2   MIASQVAVINLAAEPK    1     HEK           43.42       √                             √
  NC_Q8TD57   DNAH3      VESVLFPELK          16    Spermatozoa   39.34                                     √
  NC_Q8TD57   DNAH3      DFDLEEVMK           16    Spermatozoa   37.96                                     √
  NC_Q8TD57   DNAH3      AVVFVDDLNMPAK       16    Spermatozoa   36.67                                     √
  NC_Q8TD57   DNAH3      GNILEDETAIK         16    Spermatozoa   36.09                                     √
  NC_Q6URK8   TEPP       YCLSQNPSLDR         16    Spermatozoa   31.36                                      

Although all the analyses and the selection of the peptides for validation were carried out using the neXtProt database 20150901, the release of a new version (20160111) compelled us to compare the results at this stage with the new list of missing proteins. As shown in [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"}, all the selected proteins except DNAH3 and TEPP (with new evidence in the spermatozoa sample) were still considered missing proteins in the new release.

Validation of Missing Protein Identifications Using SRM/MRM {#sec3.8}
-----------------------------------------------------------

In order to validate the identifications of the missing proteins, two experimental strategies were designed. First, a sample with a mixture of the heavy peptides for the 17 peptides selected for validation was analyzed using MIDAS (MRM-initiated detection and sequencing), a method in which the mass spectrometer (ABSciex QTrap5500) switches from MRM to enhanced product ion scanning mode when an individual MRM is detected. Data were examined manually to verify the chromatographic peaks and the transitions detected for each peptide, and 15 peptides were used for further analysis ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_007.xlsx) Table 6). The MS/MS spectra of the heavy precursors were searched with Mascot against the neXtProt database using the target-decoy strategy with the following parameters: precursor tolerance 0.8 Da, fragment tolerance 0.6 Da, two missed cleavages, carbamidomethyl cysteine as a fixed modification, and oxidized methionine as variable modification. The identification of proteins was performed with a criterion of PSM FDR \< 1%, protein FDR \< 1%, and PAnalyzer to select only conclusive proteins. We detected 13 of the synthetic peptides, corresponding to 8 missing proteins ([Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}). In [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} we show the comparison between a selection of the fragmentation spectra obtained for the heavy peptides and the corresponding endogenous spectra found in the shotgun experiments for the peptides VESVCFPELK (DNAH3), EANVAAAIAQGIK (DNAH3), and AAGTLFGEGFR (ATAD3C) using the SDPScore.^[@ref33]^

###### Results of the Mascot Search of the Heavy Peptide Sample Using the neXtProt Database[a](#tbl7-fn1){ref-type="table-fn"}

  Peptide            Protein     Chr   Name       Max ion score   Missing in (neXtProt20160111)
  ------------------ ----------- ----- ---------- --------------- -------------------------------
  DAASCGPGAAVAAVER   NX_A6NJT0   7     UNCX       78.49           √
  VESVLFPELK         NX_Q8TD57   16    DNAH3      75.29            
  AAGTLFGEGFR        NX_Q5T2N8   1     ATAD3C     56.93           √
  MIASQVAVINLAAEPK   NX_B2RXH8   1     HNRNPCL2   55.83           √
  ADEVEQSPKPK        NX_A6NHN6   16    NPIPB15    54.39           √
  EANVAAAIAQGIK      NX_Q8TD57   16    DNAH3      52.72            
  EMCDMEQVLSK        NX_Q2VIQ3   5     KIF4B      48.67           √
  YCLSQNPSLDR        NX_Q6URK8   16    TEPP       46.26            
  MVQPMIDQSNR        NX_A8K0S8   17    MEIS3P2    45.03           √
  LYSSLLDEIR         NX_Q8TD57   16    DNAH3      44.68            
  TQTISLGQGQGPIAAK   NX_Q8TD57   16    DNAH3      44.15            
  AVVFVDDLNMPAK      NX_Q8TD57   16    DNAH3      43.37            
  DFDLEEVMK          NX_Q8TD57   16    DNAH3      39.71            
  GNILEDETAIK        NX_Q8TD57   16    DNAH3      39.6             

Conclusive proteins according to PAnalyzer were selected (PSM FDR \< 1%, Protein FDR \< 1%).

![(A) Comparison of the MS/MS spectrum of peptide EANVAAAIAQGIK from DNAH3 protein obtained in the shotgun experiment (lower) and the MS/MS spectrum for its synthetic heavy peptide (upper) obtained in the LC--SRM experiment (SDPScore = 0.88). (B) Comparison of the MS/MS spectrum of peptide VESVCFPELK from DNAH3 protein obtained in the shotgun experiment (lower) and the MS/MS spectrum for its synthetic heavy peptide (upper) obtained in the LC--SRM experiment (SDPScore = 0.90). (C) Comparison of the MS/MS spectrum of peptide AAGTLFGEGFR from ATAD3C protein obtained in the shotgun experiment (lower) and the MS/MS spectrum for its synthetic heavy peptide (upper) obtained in the LC--SRM experiment (SDPScore =0.89).](pr-2016-00437s_0009){#fig7}

The final step of the validation process was the targeting of the selected peptides by SRM to detect them in the biological samples of interest (spermatozoa and the HEK293 cell line). This approach allowed us to confirm the presence of four peptides in spermatozoa (DNAH3) and an additional peptide for the protein ATAD3C in the HEK293 cell line, as can be seen in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A. As we have mentioned before, the protein DNAH3 changed its evidence from missing protein to PE1 during the development of our study (neXtProt release 20160111). The evidence at the protein level was obtained from PeptideAtlas using a reanalysis of the spermatozoa proteome.^[@ref13]^ We validated this evidence in a set of independent samples with the detection of four proteotypic peptides. In [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}C--E we show the SRM/MRM signal for three of these peptides, and in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B we show the SRM/MRM signal for the peptide detected from ATAD3C in the HEK293 cell line.

![(A) Venn diagram with the peptides selected for detection and the results of the different stages of the validation analysis. (B) Endogenous (upper) and synthetic heavy peptide (lower) LC-SRM signals measured for the peptide AAGTLFGEGFR from ATAD3C in the HEK293 cell line. (C) Endogenous (upper) and synthetic heavy peptide (lower) LC-SRM signals measured for the peptide EANVAAAIAQGIK from DNAH3 in the spermatozoa sample. (D) Endogenous (upper) and synthetic heavy peptide (lower) LC-SRM signals measured for the peptide GNILEDETAIK from DNAH3 in the spermatozoa sample. (E) Endogenous (upper) and synthetic heavy peptide (lower) LC-SRM signals measured for the peptide VESVLFPELK from DNAH3 in the spermatozoa sample.](pr-2016-00437s_0010){#fig8}

Although we found only one peptide using LC-SRM in the HEK293 cell line, we suggest increasing the number of experiments in this sample in order to validate the presence of a large number of missing proteins using other experimental protocols or other proteomic techniques, for example antibody-based technologies. We consider this finding as an opportunity to characterize proteins with potential interest in molecular and biology research. For example, the proteins ATAD3C (ATPase Family, AAA Domain Containing 3C), validated using the LC--SRM approach, and UNCX (UNC Homeobox), detected in the shotgun data analysis following the HPP guidelines, have been previously related to embryonic development^[@ref34],[@ref35]^ and tumorigenesis.^[@ref36]^ More specifically, mutations of the ATAD3C gene have been associated with colorectal cancer (COSMIC accession codes 2230025 and 2230026).

Collectively, the validation experiments carried out proved the success of the strategy described in this manuscript to detect missing proteins using the analysis of public high throughput proteomic data sets. The analysis of the shotgun experiments of the samples enriched in missing proteins from chromosome 16 was able to detect high quality spectra assigned to a set of proteins defined as missing proteins in neXtProt release 20150901, although a small fraction of them are now considered as PE1 proteins in the current release (20160111). The analysis of synthetic heavy peptides for 17 selected peptides using a MIDAS approach and the LC-SRM analysis performed in the spermatozoa sample and the HEK293 cell line provided support to the proteomics evidence for missing protein candidates. Interestingly, we were able to confirm the presence of the protein DNAH3 in spermatozoa and ATAD3C in the HEK293 cell line using SRM/MRM. The protein DNAH3 was a missing protein in the neXtProt release used in this study, but is considered as PE1 in the current release. This observation confirms the value of the developed strategy for the annotation of missing proteins. We also provided robust evidence supporting HEK293 cells as a promising source of missing proteins.

Conclusions {#sec4}
===========

The complete characterization of the human proteome is an ambitious task which is being carried out jointly by proteomics laboratories worldwide in the framework of the HPP project.^[@ref37]^ Despite the efforts made and the resources devoted to this issue since its start in 2001, no experimental evidence for 14.70% of human proteins (neXtProt release 20160201) has yet been detected in any biological matrix. The detection of this set of proteins, known as the "missing proteins", is a huge challenge from the proteomics, bioinformatics, and statistical points of view.^[@ref8]^ In recent years, the analysis of the expression level of the protein coding genes and their tissue specificity has revealed a map with the most probable location of each missing protein in a wide variety of samples.^[@ref17]^ However, the biochemical characteristics of these proteins make their detection extremely challenging, especially if stringent statistical thresholds are applied to established the likelihood of the observations.^[@ref13],[@ref32]^ The contents of a variety of databases of proteomic experiments have been gradually incorporated into the project to define the reference human proteome, for example the PRIDE database. Using the information about all the human PSMs stored in the this database, we selected a set of target samples (we found human spermatozoa and the HEK293 cell line samples specially enriched in missing proteins), and we compared two different methods of analysis of shotgun data sets for the identification of missing proteins at the proteome level.

In an attempt to provide new horizons and guidance on how and where missing proteins should be hunted for, we propose here a nonconventional bioinformatic pipeline that relies on the use of PRIDE data sets relaxing the statistical constraints to allow the selection of PSMs that suggest the presence of peptides from missing proteins, followed by a robust validation process. We used the *in silico* digestion of the protein reference database and the selection of unique peptides (proteotypic peptides) for all the proteome to filter those spectra assignments with PSM FDR \< 1%. With this method, without the need for protein inference and protein FDR filtering, we found 182 missing protein candidates. However, in this case, the results had to be carefully analyzed by mass spectrometry experts to remove low quality assignments, and hence, the remaining PSM entered the experimental validation process based on SRM. From our findings, 17 peptides were selected for validation, and heavy peptides were synthesized to validate the identification of 13 missing proteins with SRM/MRM experiments. We identified four proteotypic peptides from the protein DNAH3 in the spermatozoa sample and one proteotypic peptide from the protein ATAD3C in the HEK293 cell line using LC-SRM assays. Therefore, we have demonstrated the feasibility of the study of missing proteins using an alternative method that combines the proper selection of the target sample based on MS experiments from public databases and a statistical analysis based on the detection of certain peptides that uniquely defined the missing proteins.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jproteome.6b00437](http://pubs.acs.org/doi/abs/10.1021/acs.jproteome.6b00437).Supporting Information Table 1: List of missing proteins with the number of proteotypic peptides using the *in silico* digestion of neXtProt (release 20150901) with Proteogest software ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_001.xlsx))Supporting Information Table 2: Mascot search engine results obtained for the different projects from the PRIDE database analyzed (PSM FDR \< 1%) ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_007.xlsx))Supporting Information Table 3: Summary of the HPP guideline results ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_002.xlsx))Supporting Information Table 4: List of the peptides from the missing proteins obtained in the analysis of the PRIDE samples after PSM FDR \< 1% filtering, intersected with the proteotypic peptides of neXtProt ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_003.xlsx))Supporting Information Table 5: Functional characterization of the missing proteins detected using the analysis of the proteotypic peptides of the neXtProt database (183 proteins) with DAVID software ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_004.xlsx))Supporting Information Table 6: List of SRM/MRM transitions designed for the detection of the peptides observed from the missing proteins in the shotgun experiments with the ABSciex Qtrap5500. ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_005.xlsx))Supporting Information File 1: Supplemental methods ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.6b00437/suppl_file/pr6b00437_si_006.pdf))

Supplementary Material
======================

###### 

pr6b00437_si_001.xlsx

###### 

pr6b00437_si_002.xlsx

###### 

pr6b00437_si_003.xlsx

###### 

pr6b00437_si_004.xlsx

###### 

pr6b00437_si_005.xlsx

###### 

pr6b00437_si_006.pdf

###### 

pr6b00437_si_007.xlsx

The authors declare no competing financial interest.

CIMA, UV, and CNIO laboratories are members of the PRBB-ISCIII platform. This study was supported by PRBB and the Carlos III National Health Institute Agreement, PRBB-ISCIII; grants SAF2014-5478-R from Ministerio de Ciencia e Innovación and ISCIII-RETIC RD06/0020 to F.J.C., grants 33/2015 from Dpto. de Salud of Gobierno de Navarra and DPI2015-68982-R from Ministerio de Ciencia e Innovación to V.S., and grant BFU2012-39482 from Ministerio de Economía y Competitividad to M.S.P. J.A.V. and N.d.T. are supported by the Wellcome Trust \[grant number WT101477MA\].
